Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig plus daratumumab vs DRd in transplant-ineligible newly diagnosed multiple myeloma
jRCT2051250155Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of etentamig in multiple myeloma (MM) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of participants with adverse events, Change in clinical activity and 2 more. Started Dec 2025; status: recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2051250155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250155.